Combined-modality treatment for stage IIIa (N2) non-small cell lung cancer:: A National Cancer Institute Intergroup Study

被引：6

作者：

Ettinger, DS ^{[1
]}

机构：

[1] Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1998年 / 42卷 / Suppl 1期

关键词：

combined-modality treatment; stage IIIA; NSCLC;

D O I：

10.1007/s002800051083

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Induction chemotherapy plus radiotherapy followed by surgery, evaluated in a number of phase II studies, is an effective treatment for patients with stage III A non-small cell lung cancer (NSCLC). The ongoing phase III National Cancer Institute Intergroup study is evaluating concurrent chemotherapy (cisplatin + etoposide)/radiotherapy followed by either surgery or additional radiotherapy followed by 2 additional cycles of chemotherapy in patients with stage III A disease. This study will help define the role of surgery and radiotherapy as part of the multimodality therapy of locoregional advanced NSCLC.

引用

页码：S71 / S74

页数：4

共 17 条

[1] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].